Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.

MLA

Schoenfeld, Adam J., et al. “Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.” Cancer Discovery, vol. 14, no. 8, Aug. 2024, pp. 1389–402. EBSCOhost, https://doi.org/10.1158/2159-8290.CD-23-1334.

APA

Schoenfeld, A. J., Lee, S. M., Doger de Spéville, B., Gettinger, S. N., Häfliger, S., Sukari, A., Papa, S., Rodríguez-Moreno, J. F., Graf Finckenstein, F., Fiaz, R., Catlett, M., Chen, G., Qi, R., Masteller, E. L., Gontcharova, V., & He, K. (2024). Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery, 14(8), 1389–1402. https://doi.org/10.1158/2159-8290.CD-23-1334

Chicago

Schoenfeld, Adam J, Sylvia M Lee, Bernard Doger de Spéville, Scott N Gettinger, Simon Häfliger, Ammar Sukari, Sophie Papa, et al. 2024. “Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.” Cancer Discovery 14 (8): 1389–1402. doi:10.1158/2159-8290.CD-23-1334.